Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model.

Goldenberg NA, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Turpie AG, Skene AM, Cutler NR, Hiatt WR; Antithrombotic Trials Leadership and Steering Group..

Blood. 2011 Feb 17;117(7):2089-92. doi: 10.1182/blood-2010-09-308858. Epub 2010 Nov 10.

2.

Clinical trials integrity: a CRO perspective.

Beach JE.

Account Res. 2001;8(3):245-60.

PMID:
12481762
3.

Guidelines, editors, pharma and the biological paradigm shift.

Singh AR, Singh SA.

Mens Sana Monogr. 2007 Jan;5(1):27-30. doi: 10.4103/0973-1229.32176.

4.

Conflicts of interest in research involving human beings.

Greco D, Diniz NM.

J Int Bioethique. 2008 Mar-Jun;19(1-2):143-54, 202-3. Review.

PMID:
18664007
5.
6.
7.

Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.

Georgias C, Grunow A, Olderog M, May A, Paulus U.

Clin Trials. 2012 Dec;9(6):781-7. doi: 10.1177/1740774512461978. Epub 2012 Oct 25.

PMID:
23104975
8.

Ethical management of conflict of interest: proposed standards for academic surgical societies.

Minter RM, Angelos P, Coimbra R, Dale P, de Vera ME, Hardacre J, Hawkins W, Kirkwood K, Matthews JB, McLoughlin J, Peralta E, Schmidt M, Zhou W, Schwarze ML.

J Am Coll Surg. 2011 Nov;213(5):677-82. doi: 10.1016/j.jamcollsurg.2011.08.003. Epub 2011 Aug 31.

PMID:
21880513
9.

Better infrastructure: industry-academia partnerships--a marriage of convenience?

Abraham E.

Crit Care Med. 2009 Jan;37(1 Suppl):S159-64. doi: 10.1097/CCM.0b013e3181920725.

PMID:
19104217
10.

A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors.

Schulman KA, Seils DM, Timbie JW, Sugarman J, Dame LA, Weinfurt KP, Mark DB, Califf RM.

N Engl J Med. 2002 Oct 24;347(17):1335-41.

11.

Ethics and industry-sponsored research.

Kuebler C, Nimmo WS, von R, Gillings D, Morgan AT, Kendle C, Covington PS.

CMAJ. 2002 Mar 5;166(5):579-80; author reply 582. No abstract available.

12.

Maintaining the trust of physicians and the public in the medical literature: report of a task force on scientific publishing of clinical trials.

Shane E, Civitelli R, Delmas PD, Drezner M, Eisman JA, Lindsay R, Lorenzo J, Miller P, Ralston S, Reid I, Siris E.

J Bone Miner Res. 2007 Nov;22(11):1661-7.

13.

Oversight of financial conflicts of interest in commercially sponsored research in academic and nonacademic settings.

Weinfurt KP, Hall MA, Hardy NC, Friedman JY, Schulman KA, Sugarman J.

J Gen Intern Med. 2010 May;25(5):460-4. doi: 10.1007/s11606-010-1264-6. Epub 2010 Feb 26.

14.

Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.

Lieberman R, Nelson WG, Sakr WA, Meyskens FL Jr, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM.

Urology. 2001 Apr;57(4 Suppl 1):4-27.

PMID:
11295590
15.

Clinical investigators and the pharmaceutical industry.

Newman TJ.

N Engl J Med. 2000 Aug 17;343(7):510-1. No abstract available.

16.

Better regulation of industry-sponsored clinical trials is long overdue.

Wynia M, Boren D.

J Law Med Ethics. 2009 Fall;37(3):410-9, 395. doi: 10.1111/j.1748-720X.2009.00402.x.

PMID:
19723252
17.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd..

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
18.

Emergency medicine leadership in industry-sponsored clinical trials.

Newgard CD, Kim S, Camargo CA Jr.

Acad Emerg Med. 2003 Feb;10(2):169-74.

19.

Academic medical centers' standards for clinical-trial agreements with industry.

Mello MM, Clarridge BR, Studdert DM.

N Engl J Med. 2005 May 26;352(21):2202-10.

20.

Gag clauses in clinical-trial agreements.

Steinbrook R.

N Engl J Med. 2005 May 26;352(21):2160-2. No abstract available.

PMID:
15917381

Supplemental Content

Support Center